Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606539 | 0.80 | ALDH1A1 (0.50) | ALDH1A1GPR35TDP1TSHRHTT | |
| SCHEMBL27579425 | 0.80 | ALDH1A1 (0.47) | ALDH1A1GPR35TDP1TSHRHTT | |
| SCHEMBL3942261 | 0.80 | ALDH1A1 (0.50) | ALDH1A1GPR35TDP1TSHRHTT | |
| SCHEMBL2178791 | 0.78 | ALDH1A1 (0.50) | ALDH1A1GPR35TDP1TSHRHTT | |
| SCHEMBL30557784 | 0.78 | ALDH1A1 (0.50) | ALDH1A1GPR35TDP1TSHRHTT | |
| SCHEMBL14659678 | 0.78 | ALDH1A1 (0.44) | ALDH1A1GPR35TDP1HTTMEN1 | |
| Ammonia Solution, Strong SCHEMBL27652614 | 0.78 | ALDH1A1 (0.48) | ALDH1A1GPR35TDP1TSHRHTT | |
| SCHEMBL12065144 | 0.78 | ALDH1A1 (0.48) | ALDH1A1GPR35TDP1TSHRHTT | |
| SCHEMBL1817196 | 0.78 | HTT (0.50) | ALDH1A1TDP1HTTGAAMEN1 | |
| SCHEMBL31481312 | 0.77 | ALDH1A1 (0.44) | ALDH1A1GPR35TDP1TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118459299-A | Gamma site deuteration method of fatty amine compound | 浙大宁波理工学院 | 2024-08-09 | — | — | CN | claimed |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4558505-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119923398-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119742448-A | High-voltage additive for lithium battery electrolyte, electrolyte and lithium ion battery | 中国科学院宁波材料技术与工程研究所 | 2025-04-01 | — | — | CN | disclosed |
| CN-118459299-A | Gamma site deuteration method of fatty amine compound | 浙大宁波理工学院 | 2024-08-09 | — | — | CN | disclosed |
| WO-2024020534-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023147545-A2 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3412675-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| CN-105916857-B | Pyrrolopyrrolone derivatives and its purposes as BET inhibitor | 诺华股份有限公司 | 2018-06-22 | — | — | CN | disclosed |
| WO-2010014687-A1 | SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014280-A1 | PYRAZINONE MODULATOR OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029684-A1 | Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20100029684-A1 | Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20100029684-A1 | Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| EP-2125734-A2 | NOVEL MICROBIOCIDES | Syngeta Participations AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008101682-A2 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101682-A2 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| CN-101128454-A | Pyridine carboxamide derivatives for use as anticancer agents | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029684-A1 | Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity | CRH, CRHR1, CRHR2 | ALDH1A1 2086/4885GPR35 60/4885TDP1 4713/4885 |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | CCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MALT1 | ALDH1A1 2214/4885GPR35 2031/4885TDP1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.